combination targeted adjuvant therapy doubles relapse-free survival in stage iii melanoma
Published 6 years ago • 410 plays • Length 6:25Download video MP4
Download video MP3
Similar videos
-
8:48
combi-ad: dual-targeted therapy for stage 3 melanoma
-
0:56
5-year follow-up: dabrafenib plus trametinib reduces relapse risk in melanoma
-
5:54
keynote-716: adjuvant therapy with pembrolizumab for patients with high-risk stage ii melanoma
-
1:22
the personalization of neoadjuvant immunotherapy in stage iii melanoma
-
3:05
targeting therapies improve progression-free survival in melanoma
-
1:36
results from keynote-716: adjuvant therapy with pembrolizumab in high-risk stage ii melanoma
-
2:46
neoadjuvant therapy in bulky stage iii melanoma
-
2:06
improving survival in stage iii melanoma
-
1:30
adjuvant therapy for high-risk melanoma
-
10:18
adjuvant ipilimumab improves recurrence-free survival in high-risk stage iii melanoma
-
4:12
adjuvant therapy in melanoma: combi-ad trial
-
3:37
adjuvant therapy for resected stage iii melanoma
-
4:02
prado: personalized response-driven surgery and adjuvant therapy in stage iii melanoma
-
2:24
prado: personalized response-driven therapy in resectable stage iii melanoma
-
2:05
dr. weber on adjuvant approaches in stage iii melanoma
-
0:33
keynote-716: pembrolizumab in stage 2b/2c cutaneous melanoma
-
7:39
adjuvant nivolumab versus ipilimumab for resected stage iii/iv melanoma
-
5:00
adjuvant therapy for stage iii melanoma
-
7:34
adjuvant therapy for melanoma: nivolumab, pembrolizumab, ipilimumab, dabrafenib and trametinib